Enclomiphene vs Clomid vs TRT: What Each One Actually Does to Your Testosterone

Why you are comparing these three

You are 35 to 55. Energy flattens by mid-afternoon. Libido is quieter than it was. A lab report says "borderline." Then the ads find you: "raise your own testosterone," "fertility-friendly," "no shutdown." The pitch is tailored to men exactly like you, because men exactly like you are the market.

None of this means you are broken. It means you need the physiology separated from the sales copy before you decide anything. Three options get bundled together in those ads. One is an approved drug used off-label. One is an unapproved drug that FDA is still evaluating for compounding. One is the established prescription that replaces the hormone outright. They are not interchangeable, and the differences are the point.

How each one works

Testosterone therapy works from the outside in. It supplies the hormone your body is under-producing. Your brain reads the higher level and dials down its own signal, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Those two hormones are what tell your testes to make testosterone and sperm. Cut the signal and both fall.

Clomiphene and enclomiphene work from the top down. They are selective estrogen receptor modulators (SERMs). Estrogen normally tells the hypothalamus and pituitary to ease off; a SERM blocks that message, so LH and FSH rise and your testes respond by making more of your own testosterone. In the 2013 pharmacology study, enclomiphene raised total testosterone into the normal range and pushed LH and FSH above it, while transdermal testosterone raised testosterone and suppressed LH.

The difference between the two SERMs is chemistry. Clomid is a mixture of two mirror-image molecules. One is enclomiphene, the trans-isomer, which does the blocking. The other is zuclomiphene, which is weakly estrogenic and clears from the body slowly. Enclomiphene on its own drops the second isomer. That is a real pharmacological distinction. Whether it changes how you feel over months is a question the trials were not built to answer.

Mechanism is a reason to run a trial. It is not a result.

Approval and legal status, side by side

Enclomiphene has never been approved by FDA. Repros Therapeutics submitted it as Androxal for secondary hypogonadism in overweight men. On December 1, 2015, the company reported receiving a complete response letter: FDA said that, given recent scientific developments, the phase 3 design was no longer adequate to demonstrate clinical benefit, recommended one or more additional phase 3 studies, and raised concerns about study entry criteria, titration, and bioanalytical method validation. That account is the company's statement; FDA's letter itself is not public in the record this page checked.

Since then the substance has lived in FDA's compounding review. It was one of four substances discussed at the June 8, 2022 Pharmacy Compounding Advisory Committee meeting. FDA's list of bulk drug substances nominated for compounding, updated May 14, 2026, places enclomiphene citrate in Category 1, "bulk drug substances under evaluation." Category 1 is not an approval and not a safety finding. It is a holding pattern.

Clomid is different. Clomiphene citrate is FDA-approved to treat ovulatory dysfunction in women desiring pregnancy. The label is explicit that there are no adequate, well-controlled studies showing it works for male infertility. When a clinician prescribes it to raise a man's testosterone, that is off-label use of an approved drug, which is legal and common, and which carries less regulatory certainty than an approved indication.

Testosterone is a prescription drug. Congress placed anabolic steroids, testosterone included, in schedule III of the Controlled Substances Act, and the DEA describes testosterone and several of its forms as the main anabolic steroids prescribed in the United States. The AUA guideline adds one more line: commercially manufactured testosterone should be prescribed rather than compounded testosterone when possible.

What the human evidence shows

Enclomiphene's best data are two parallel phase III trials, ZA-304 and ZA-305, published in 2016. They randomized overweight men aged 18 to 60 with secondary hypogonadism, defined by an early-morning total testosterone of 300 ng/dL or lower and LH under 9.4 IU/L, to enclomiphene, testosterone gel, or placebo for 16 weeks. Total testosterone rose in every active arm. Enclomiphene kept sperm concentration in the normal range; the gel arm showed a marked reduction in spermatogenesis. A phase II trial published in 2014 found the same pattern. What those trials did not measure: how men felt a year later, or what happened to their health over years.

The cleanest summary of SERMs in men is a 2025 meta-analysis of 10 randomized trials, 819 men, pooling clomiphene and enclomiphene. Against placebo, total testosterone rose by a mean of 273.76 ng/dL, with moderate certainty. Against testosterone gel, there was no meaningful difference in testosterone, and sperm concentration was higher with the SERMs by about 70 million/mL, with far fewer men dropping below the 15 million/mL line. The authors say plainly that the analysis is underpowered for safety.

Clomid on its own rests on weaker ground. A 2022 systematic review found 19 studies and 1,642 men, but only four of the studies were randomized; the rest were observational. Testosterone rose and symptom scores improved. Treat that as a consistent signal from mostly uncontrolled data, not as proof.

TRT has the benchmark. TRAVERSE randomized 5,246 men aged 45 to 80 with hypogonadism and existing or high cardiovascular risk to testosterone gel or placebo. Major cardiac events occurred in 7.0% with testosterone versus 7.3% with placebo, meeting the trial's standard for not being worse. Atrial fibrillation, acute kidney injury, and pulmonary embolism were more frequent with testosterone. That is what real safety evidence looks like: thousands of men and named risks. Hold the SERM data to the same standard, and notice how far short it falls.

Fertility: the real reason men compare these

Strip away the ads and this is the actual question. Exogenous testosterone suppresses the LH and FSH signal, and sperm production falls with it. The AUA guideline is direct: exogenous testosterone should not be prescribed to men who are currently trying to conceive. The Endocrine Society guideline recommends against starting testosterone in men planning fertility in the near term. The AUA guideline adds that a man interested in fertility should have a reproductive health evaluation before any treatment.

The SERM case is that it raises testosterone without that cost. The AUA guideline allows for it: clinicians may use aromatase inhibitors, human chorionic gonadotropin, selective estrogen receptor modulators, or a combination of them in men with testosterone deficiency who want to maintain fertility. It grades that as a conditional recommendation on Grade C evidence. Read both halves. The option is on the table, and the evidence behind it is the weakest grade the guideline uses.

Enclomiphene versus Clomid for fertility specifically is an open question. The phase III enclomiphene trials compared it with testosterone gel, not with Clomid. The meta-analysis pools the two. If someone tells you one SERM is proven to protect fertility more than the other, ask for the head-to-head trial. There is not one in this source pack.

The decision belongs with a urologist or reproductive endocrinologist, with a semen analysis and an FSH level in front of them. Not with an ad, and not with this page.

Side effects and what gets monitored

Clomid's label carries the clearest warning in this comparison: blurring or other visual symptoms such as spots or flashes, more common with higher total dose and longer treatment, and the instruction to stop and get a prompt ophthalmological evaluation if they appear. The label also notes testicular tumors and gynecomastia reported in males. In the 2022 review, side effects were reported in under 10% of study populations, with no serious adverse events.

Enclomiphene's trials were short. In the 2025 meta-analysis, adverse-event rates did not differ between SERM, gel, and placebo arms, and the rare discontinuations were for elevated hematocrit in both the SERM and gel arms and elevated PSA in one SERM patient. Because both SERMs raise estradiol along with testosterone, estradiol is on the monitoring list.

TRT's named risks come from TRAVERSE: more atrial fibrillation, acute kidney injury, and pulmonary embolism than placebo. Hematocrit is the routine concern; the AUA guideline says to measure hemoglobin and hematocrit before starting and to warn patients about polycythemia. PSA is measured in men over 40 before starting.

• All three: total testosterone on a schedule, estradiol if breast symptoms or gynecomastia appear, PSA in men over 40.
• SERMs: the AUA follow-up table calls for an LH check four weeks after starting if testosterone stays low, and vision changes are a stop-and-call signal for clomiphene.
• TRT: hemoglobin and hematocrit before and during, with the polycythemia conversation up front.
• No arm in these trials was large enough or long enough to rank the three on safety. Anyone who ranks them for you is guessing.

Cost and access, without numbers

Each path runs through a prescription and ongoing labs. Enclomiphene has no approved product, which means any supply is compounded and sits inside FDA's unresolved review. Clomid is a manufactured, approved drug prescribed off-label for men. Testosterone is a manufactured, approved, controlled drug with a monitoring schedule built around it.

Many of the online clinics that sell enclomiphene also publish the comparison articles that rank it first. This page links to none of them and quotes no prices. The honest version of "cost" is this: factor in the labs, the follow-up visits, and the possibility that the thing you start is the thing you stay on, before you compare any monthly figure.

Who each path fits, and who it does not

These are starting points for a conversation, not a sorting hat. Every line below assumes a confirmed diagnosis and a clinician who knows your full history.

What to do first

Before any of the three, get the diagnosis right. The AUA guideline uses a total testosterone below 300 ng/dL as a reasonable cut-off, and requires two early-morning measurements on separate occasions before calling it low. The Endocrine Society adds that the draw should be fasting and the assay reliable. Then the clinician looks for the cause, because a cause is something you can act on, and because secondary hypogonadism from weight, sleep, or medication has its own fixes.

Write down your symptoms before the appointment. Put fertility on the table at the first visit if children are a possibility in the next few years, because that single answer changes which of the three options is even on the list. If your numbers are borderline, the lifestyle levers in the foundation protocol are not a consolation prize; they are the first-line move the guidelines assume you have already made.

Talk to a qualified clinician before starting, stopping, or combining any of these.

Start with the signs of testosterone imbalance checklist before the appointment.

The enclomiphene-or-TRT question needs a clinician and two blood draws. The afternoon crash that sent you here does not have to wait. Low cellular energy has its own biology, and that part you can work on today.

Read NAD+ for men and NAD+ for energy for what that evidence does and does not show.